At 1-year, minimal stent area does not increase, and target vessel failure does not decrease, with the use of routine orbital atherectomy pre-drug-eluting stent (DES) implantation compared with using a balloon angioplasty approach in patients with severely calcified lesions, the ECLIPSE trial shows.